Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital

The last decade in oncology has witnessed impressive response rates with targeted therapies, largely because of collaborative efforts at understanding tumor biology and careful patient selection based on molecular fingerprinting of the tumor. Consequently, there has been a push toward routine molecu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bardia, Aditya, Iafrate, John A., Sundaresan, Tilak, Younger, Jerry, Nardi, Valentina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Precision Medicine Clinic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016066/
https://www.ncbi.nlm.nih.gov/pubmed/27551012
http://dx.doi.org/10.1634/theoncologist.2016-0240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016066/
https://www.ncbi.nlm.nih.gov/pubmed/27551012
http://dx.doi.org/10.1634/theoncologist.2016-0240

Ejemplares similares